drugset / Trial / NCT06150898
Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
RandomizedParallel-groupOpen-labelOther
Summary
Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer. To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug. Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs
Timeline
- Start
- 2025-05-12
- Primary completion
- 2027-04-20
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketorolac | Other / unclassified | 10 mg | Oral |
| Subject | Pregabalin | Small molecule | 75 mg | — |
| Background | Omeprazole | Other / unclassified | 20 mg | — |